Randomized controlled studies consistently demonstrate that normalizing the Hb level
of patients with CKD with ESAs is associated with poorer outcomes than a Hb target in
the 9.0 to 11.5 g/dL range.
The characteristic lipid profile of patients with chronic kidney disease consists of high
triglycerides and low high-density lipoprotein (HDL) cholesterol concentrations,
whereas total and low-density lipoprotein (LDL) cholesterol are normal or even low.
Membranous nephropathy occurs as an idiopathic (75% of cases) or secondary disease
(autoimmune diseases, infection, and malignancies), where up to 70% of patients will
have nephrotic syndrome at the time of presentation. It is a chronic disease, with spontaneous
remission and relapses clearly documented.
Current data suggest that new therapeutic agents such as rituximab and synthetic
adrenocorticotropic hormone (ACTH) are effective in reducing proteinuria while having
few adverse effects.
. MN can recur after kidney transplantation in approximately 42% of patients, causing
proteinuria, allograft dysfunction, and graft failure. Recurrence most often occurs during
the first year.
Immunoglobulin A (IgA) nephropathy is the most common biopsy-proven primary
glomerulonephritis in the world.
The classical presentation is painless gross hematuria 2 to 3 days after an upper respiratory
infection.
of patients with CKD with ESAs is associated with poorer outcomes than a Hb target in
the 9.0 to 11.5 g/dL range.
The characteristic lipid profile of patients with chronic kidney disease consists of high
triglycerides and low high-density lipoprotein (HDL) cholesterol concentrations,
whereas total and low-density lipoprotein (LDL) cholesterol are normal or even low.
Membranous nephropathy occurs as an idiopathic (75% of cases) or secondary disease
(autoimmune diseases, infection, and malignancies), where up to 70% of patients will
have nephrotic syndrome at the time of presentation. It is a chronic disease, with spontaneous
remission and relapses clearly documented.
Current data suggest that new therapeutic agents such as rituximab and synthetic
adrenocorticotropic hormone (ACTH) are effective in reducing proteinuria while having
few adverse effects.
. MN can recur after kidney transplantation in approximately 42% of patients, causing
proteinuria, allograft dysfunction, and graft failure. Recurrence most often occurs during
the first year.
Immunoglobulin A (IgA) nephropathy is the most common biopsy-proven primary
glomerulonephritis in the world.
The classical presentation is painless gross hematuria 2 to 3 days after an upper respiratory
infection.
